Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604553 | 0.99 | NPSR1 (0.34) | NPSR1KMT2ATDP1KDM4EPOLB | |
| SCHEMBL5138688 | 0.86 | HSD11B1 (0.42) | NPSR1KMT2ATDP1 | |
| SCHEMBL5025303 | 0.86 | HSD11B1 (0.42) | NPSR1KMT2ATDP1 | |
| SCHEMBL1605949 | 0.86 | HSD11B1 (0.42) | NPSR1KMT2ATDP1 | |
| SCHEMBL5016418 | 0.83 | HSD11B1 (0.40) | NPSR1KMT2ATDP1 | |
| SCHEMBL1605628 | 0.83 | HSD11B1 (0.40) | NPSR1KMT2ATDP1 | |
| SCHEMBL5630610 | 0.83 | HSD11B1 (0.40) | NPSR1KMT2ATDP1 | |
| SCHEMBL5016864 | 0.83 | HSD11B1 (0.40) | NPSR1KMT2ATDP1 | |
| SCHEMBL5065069 | 0.83 | HSD11B1 (0.40) | NPSR1KMT2ATDP1 | |
| SCHEMBL1605987 | 0.82 | NPSR1 (0.32) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | NPSR1 2386/4885KMT2A 3049/4885TDP1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.